Hostname: page-component-6766d58669-bkrcr Total loading time: 0 Render date: 2026-05-17T22:06:44.062Z Has data issue: false hasContentIssue false

Harnessing the power of genomics in hypertension: tip of the iceberg?

Published online by Cambridge University Press:  04 February 2025

Hafiz Naderi
Affiliation:
William Harvey Research Institute, Queen Mary University of London, London, UK Barts Heart Centre, St Bartholomew’s Hospital, West Smithfield, London, UK National Institute of Health and Care Research Barts Biomedical Research Centre, Queen Mary University of London, London, UK
Helen R. Warren
Affiliation:
William Harvey Research Institute, Queen Mary University of London, London, UK National Institute of Health and Care Research Barts Biomedical Research Centre, Queen Mary University of London, London, UK
Patricia B. Munroe*
Affiliation:
William Harvey Research Institute, Queen Mary University of London, London, UK National Institute of Health and Care Research Barts Biomedical Research Centre, Queen Mary University of London, London, UK
*
Corresponding author: Patricia B. Munroe; Email: p.b.munroe@qmul.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Despite the blaze of advancing knowledge on its complex genetic architecture, hypertension remains an elusive condition. Genetic studies of blood pressure have yielded bitter-sweet results thus far with the identification of more than 2,000 genetic loci, though the candidate causal genes and biological pathways remain largely unknown. The era of big data and sophisticated statistical tools has propelled insights into pathophysiology and causal inferences. However, new genetic risk tools for hypertension are the tip of the iceberg, and applications of genomic technology are likely to proliferate. We review the genomics of hypertension, exploring the significant milestones in our current understanding of this condition and the progress towards personalised treatment and management for hypertension.

Topics structure

Topic(s)

Subtopic(s)

Information

Type
Review
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press
Figure 0

Figure 1. Key advances in hypertension genomics.

Author comment: Harnessing the power of genomics in hypertension: tip of the iceberg? — R0/PR1

Comments

Dear Anna,

We have prepared a perspective article for consideration for publication in Cambridge Prisms: Precision Medicine. The idea of writing this article stems from the BIHS essay competition last year which Hafiz had entered. Subsequent to this he has developed the essay.

In the article we explore the significant milestones to our current understanding of hypertension. We highlight key landmarks in blood pressure related research, including early epidemiologic insights from the Pickering-Platt debate in the 1950s and beyond, the big boom in gene mapping of the 1990s and the wave of advancing technology paving the way for the era of genome wide association studies at the turn of the millennium. We also explore the development of pharmacogenomics in hypertension and the role of large-scale biobanks in drug development together with the challenges and future landscape.

We hope this article will be of interest to the Cambridge Prisms: Precision Medicine readership.

All authors have read and approved the submission of the manuscript; the manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language.

We look forward to hearing from you and thank you in advance for your consideration.

Best wishes,

Patricia Munroe, PhD, FMedSci

Review: Harnessing the power of genomics in hypertension: tip of the iceberg? — R0/PR2

Conflict of interest statement

Reviewer declares none.

Comments

This manuscript focuses on genomic research on hypertension and discusses the historical development, current progress and future prospects of this field. But there are still some problems.

Major comments:

a) It is suggested that an additional paragraph be added to the Introduction section to provide more specific information on the clinical importance of hypertension, the limitations of existing treatments, and the potential role of genomics in addressing these issues.

b) Consider adding a timeline chart that visually illustrates the key milestones from the Platt-Pickering debate in the 1950s to modern large-scale GWAS studies.

c) The manuscript mentioned a variety of research methods, such as GWAS, PRS, etc. A section could be added to discuss the advantages and disadvantages of these methods and their specific applications in hypertension research.

d) To explore the advantages of GWAS in discovering new gene loci and its limitations in explaining causal relationships.

e) Expand the scope of multi-omics research and discuss how multi-omics integration can help us understand the molecular mechanisms of hypertension more comprehensively.

f) The manuscript did not explore sex differences in hypertension genomics research.

g) The manuscript mainly focuses on genetic factors, but there is less analysis of the interaction between genes and environmental factors (such as diet, stress, lifestyle, etc.).

h) Single-cell sequencing technology applications were not mentioned.

i) The manuscript did not discuss the potential application of gene editing technologies (such as CRISPR-Cas9) in the treatment of hypertension, which is an important direction for future genomic research.

j) nsights into specific barriers to translating genomic discoveries into clinical practice.

k) The ethical issues that may arise from genomics research and applications, such as genetic information privacy and genetic discrimination, have not been fully discussed.

Review: Harnessing the power of genomics in hypertension: tip of the iceberg? — R0/PR3

Conflict of interest statement

Reviewer declares none.

Comments

While the present work contributes to this important field, I believe it could be strengthened by considering some recent advances and perspectives in hypertension genomics research.

Please consider the following points:

1. Integration of Multi-Omics Data:

The field is moving towards integrating various ‘omics’ data (genomics, transcriptomics, proteomics, metabolomics) to better understand the pathophysiology of hypertension. Please discuss how this multi-omics approach is providing valuable insights into blood pressure regulation and potential therapeutic targets.

2. Mendelian Randomization Studies

Recent Mendelian randomization studies have been instrumental in identifying causal pathways for hypertension. It would strengthen your manuscript to include several sentences on how these studies are contributing to our understanding of hypertension etiology and potential interventions.

3. Rare Variants and Mendelian Forms of Hypertension:

While the current paper focuses on common variants of primary hypertension, it’s important to also address the role of rare variants and Mendelian forms of hypertension. These can provide valuable insights into blood pressure regulation mechanisms and potential therapeutic targets.

4. Future Directions:

Please discuss the potential of integrating genomic information with clinical data to improve risk prediction and treatment strategies.

Your work significantly contributes to the field of hypertension genomics; however, it may be further strengthened by incorporating recent advances and perspectives. Consider the following points:

1. **Integration of Multi-Omics Data**:

The field is advancing towards integrating various ‘omics’ data, including genomics, transcriptomics, proteomics, and metabolomics, to enhance the understanding of hypertension pathophysiology. Discussing this multi-omics approach could enrich your paper by highlighting how it provides insights into blood pressure regulation and identifies potential therapeutic targets.

2. **Mendelian Randomization Studies**:

Recent Mendelian randomization studies have been pivotal in identifying causal pathways for hypertension. Incorporating a discussion on how these studies advance our understanding of hypertension etiology and inform potential interventions would add substantial value to your manuscript.

3. **Rare Variants and Mendelian Forms of Hypertension**:

While the current focus is on common variants, it is crucial to address the role of rare variants and Mendelian forms of hypertension. This inclusion could offer critical insights into mechanisms of blood pressure regulation and potential therapeutic targets.

4. **Future Directions**:

It is advisable to explore the potential of integrating genomic information with clinical data to enhance risk prediction and inform treatment strategies. This discussion could serve as a forward-looking component of your work.

Recommendation: Harnessing the power of genomics in hypertension: tip of the iceberg? — R0/PR4

Comments

No accompanying comment.

Decision: Harnessing the power of genomics in hypertension: tip of the iceberg? — R0/PR5

Comments

No accompanying comment.

Author comment: Harnessing the power of genomics in hypertension: tip of the iceberg? — R1/PR6

Comments

No accompanying comment.

Recommendation: Harnessing the power of genomics in hypertension: tip of the iceberg? — R1/PR7

Comments

No accompanying comment.

Decision: Harnessing the power of genomics in hypertension: tip of the iceberg? — R1/PR8

Comments

No accompanying comment.